Stock Groups

Europe approves Merck’s plant to make J&J COVID-19 vaccine By Reuters

by Mike Robinson

[ad_1]

© Reuters. FILE PHOTO: FILE PHOTO: The Merck logo is seen at a gate to the Merck & Co campus in Rahway, New Jersey, U.S., July 12, 2018. REUTERS/Brendan McDermid/File Photo/File Photo/File Photo

(Reuters) – The European Medicines Agency (EMA) said on Thursday it had approved U.S. drugmaker Merck & Co Inc’s manufacturing site in West Point, Pennsylvania to make Johnson & Johnson (NYSE:)’s COVID-19 vaccine.

Merck, which had already scrapped two COVID-19 experimental vaccines, agreed earlier this year to take its shot.

The U.S. government at that time invoked the Defense Production Act to help equip two Merck plants to make the J&J vaccine.

The EMA said Merck’s site, to become operational immediately, was expected to support the continued supply of J&J’s COVID-19 vaccine in the European Union.

Disclaimer Fusion MediaWe remind you that this site does not contain accurate or real-time data. CFDs are stocks, indexes or futures. The prices of Forex and CFDs are not supplied by exchanges. They are instead provided by market makers. As such, the prices might not reflect market values and could be incorrect. Fusion Media is not responsible for trading losses that may be incurred as a consequence of the use of this data.

Fusion MediaFusion Media or any other person involved in the website will not be held responsible for any loss or damage resulting from reliance on this information, including charts, buy/sell signals, and data. Trading the financial markets is one of most risky investment options. Please make sure you are fully aware about the costs and risks involved.



[ad_2]